Evidence map›Paper›PMID 27373157›Full record

ArticleCell reports2016

Identification and Targeting of Long-Term Tumor-Propagating Cells in Small Cell Lung Cancer.

Nadine S Jahchan, Jing Shan Lim, Becky Bola, Karen Morris, Garrett Seitz, Kim Q Tran, Lei Xu, Francesca Trapani, Christopher J Morrow, Sandra Cristea and 13 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 89 citations in OpenAlex.

  1. Public Transcriptomic Data Mining for SCLC: From Candidate Ma rkers to Therapeutic Exploration.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Lineage Plasticity in SCLC Generates Non-Neuroendocrine Cells Primed for Vasculogenic Mimicry.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2023
    Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 6 institutions in 3 countries.

Nadine S JahchanDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA.
Jing Shan LimDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA.
Becky BolaClinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, University of Manchester and Manchester Cancer Research Centre, Wilmslow Road, Manchester M20 4BX, UK.
Karen MorrisClinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, University of Manchester and Manchester Cancer Research Centre, Wilmslow Road, Manchester M20 4BX, UK.
Garrett SeitzDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA.
Kim Q TranDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA.
Lei XuDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA.
Francesca TrapaniClinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, University of Manchester and Manchester Cancer Research Centre, Wilmslow Road, Manchester M20 4BX, UK.
Christopher J MorrowClinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, University of Manchester and Manchester Cancer Research Centre, Wilmslow Road, Manchester M20 4BX, UK.
Sandra CristeaDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA.
Garry L ColesDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA.
Dian YangDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA.
Dedeepya VakaDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA.
Michael S KaretaDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA.
Julie GeorgeMedical Faculty, Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn and Center for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, Germany.
Pawel K MazurDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA.
Thuyen NguyenDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA.
Wade C AndersonStemcentrx Inc., South San Francisco, CA 94080, USA.
Scott J DyllaStemcentrx Inc., South San Francisco, CA 94080, USA.
Fiona BlackhallInstitute of Cancer Sciences, University of Manchester and Manchester Cancer Research Centre, Wilmslow Road, Manchester M20 4BX, UK.
Martin PeiferMedical Faculty, Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn and Center for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, Germany.
Caroline DiveClinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, University of Manchester and Manchester Cancer Research Centre, Wilmslow Road, Manchester M20 4BX, UK.
Julien SageDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA. Electronic address: julsage@stanford.edu.
Stanford University · USUniversity of Manchester · GBCancer Research UK Manchester Institute · GBChemoCentryx (United States) · USUniversity of Cologne · DECancer Research UK Manchester Centre

Funding

Translational Oncology Research Program (Project-005)P30CA124435 · NCI · STANFORD UNIVERSITY · PI Melinda L. Telli · 2007 to 2026
$71.4M
Notch signaling in small cell lung carcinomaR01CA201513 · NCI · STANFORD UNIVERSITY · PI SAGE, JULIEN · 2016 to 2019
$1.5M
The SMYD3-ERK5 signaling module in pancreatic cancerR00CA197816 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MAZUR, PAWEL K. · 2017 to 2019
$732k
The SMYD3-ERK5 signaling module in pancreatic cancerK99CA197816 · NCI · STANFORD UNIVERSITY · PI MAZUR, PAWEL K. · 2015 to 2016
$294k
Cancer Research UK 19278Cancer Research UK 20465Cancer Research UK C5759/A20971NCI NIH HHS K99 CA197816NCI NIH HHS P30 CA124435NCI NIH HHS R00 CA197816NCI NIH HHS R01 CA201513
6 · The paper itself

Abstract

Small cell lung cancer (SCLC) is a neuroendocrine lung cancer characterized by fast growth, early dissemination, and rapid resistance to chemotherapy. We identified a population of long-term tumor-propagating cells (TPCs) in a mouse model of SCLC. This population, marked by high levels of EpCAM and CD24, is also prevalent in human primary SCLC tumors. Murine SCLC TPCs are numerous and highly proliferative but not intrinsically chemoresistant, indicating that not all clinical features of SCLC are linked to TPCs. SCLC TPCs possess a distinct transcriptional profile compared to non-TPCs, including elevated MYC activity. Genetic and pharmacological inhibition of MYC in SCLC cells to non-TPC levels inhibits long-term propagation but not short-term growth. These studies identify a highly tumorigenic population of SCLC cells in mouse models, cell lines, and patient tumors and a means to target them in this most fatal form of lung cancer.

Indexed as

AnimalsCarcinogenesisCell Line, TumorCell ProliferationDisease Models, AnimalHumansLung NeoplasmsMiceSmall Cell Lung CarcinomaTranscription, Genetic

Identifiers

PMID27373157
PMCPMC4956576
OpenAlexW2471304671

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.